Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Theravance Biopharma's Days Inventory or its related term are showing as below:
During the past 13 years, Theravance Biopharma's highest Days Inventory was 8591.54. The lowest was 879.21. And the median was 1401.54.
TBPH's Days Inventory is not ranked *
in the Biotechnology industry.
Industry Median: 182.94 * Ranked among companies with meaningful Days Inventory only.
Theravance Biopharma's Days Inventory
stayed the same
from Mar. 2025 (0.00) to Mar. 2026 (0.00).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Theravance Biopharma's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.00.
Theravance Biopharma (NAS:TBPH) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Theravance Biopharma's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Theravance Biopharma's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Theravance Biopharma Days Inventory Related Terms
Theravance Biopharma Days Inventory Historical Data
* Premium members only.
The historical data trend for Theravance Biopharma's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TBPH vs ABUS, SANA, ANNX: Days Inventory Comparison
For the Biotechnology subindustry, Theravance Biopharma's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Theravance Biopharma Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Theravance Biopharma's Days Inventory distribution charts can be found below:
* The bar in red indicates where Theravance Biopharma's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Theravance Biopharma (TBPH) has a Days Inventory of 0.00 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Theravance Biopharma and its competitors. Over the past decade, Theravance Biopharma's Days Inventory has ranged from 879.21 to 8,591.54. According to the industry distribution chart, Theravance Biopharma ranks #999999 out of 638 companies in the Biotechnology industry.
Is Theravance Biopharma's Days Inventory too high?
Theravance Biopharma's current Days Inventory is 0.00. Over the past 10 years, this metric has ranged from a low of 879.21 to a high of 8,591.54. Based on the distribution chart, Theravance Biopharma ranks #999999 out of 638 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Theravance Biopharma has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Theravance Biopharma's Days Inventory compare to ABUS and SANA?
According to the Biotechnology industry distribution chart, Theravance Biopharma ranks #999999 out of 638 companies for Days Inventory. This places Theravance Biopharma in the lower half of its industry. The industry median Days Inventory is 182.94. Historically, Theravance Biopharma's own Days Inventory has ranged from 879.21 to 8,591.54 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 182.94, based on 638 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Theravance Biopharma and its competitors. For the Biotechnology industry, the median Days Inventory is 182.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Theravance Biopharma's current Days Inventory is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Theravance Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Theravance Biopharma (TBPH) is currently considered Modestly Undervalued. The stock's GF Value™ is $18.67, compared to a current price of $16.86 — trading 9.7% below its estimated fair value. The current Days Inventory is 0.00. Theravance Biopharma's overall GF Score™ is 72/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Theravance Biopharma (TBPH), the current Days Inventory is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Theravance Biopharma (TBPH) Overvalued in 2026?
Based on GuruFocus' analysis, Theravance Biopharma stock appears to be undervalued.
The current stock price of $16.86 is trading 9.7% below its estimated GF Value™ of $18.67.
GuruFocus considers Theravance Biopharma to be Modestly Undervalued.
Key valuation signals for TBPH:
Days Inventory: 0.00
GF Value™: $18.67 vs. price of $16.86 (9.7% below fair value)
No single metric tells the full story. See the TBPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.
72GF Score
Get the complete analysis for TBPH
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TBPH has been successfully added to your 
